Jun-Ichi Tanabe
Toray Industries
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jun-Ichi Tanabe.
Immunology | 2007
Jun-Ichi Tanabe; Akiko Izawa; Natsumi Takemi; Yasushi Miyauchi; Yuichi Torii; Hiromi Tsuchiyama; Tomohiko Suzuki; Saburo Sone; Kazuki Ando
Type I interferons (IFNs), IFN‐α and IFN‐β, are widely used for treating chronic hepatitis C. Although retrospective studies have suggested that type I IFNs have direct antifibrotic effects, little is known about these mechanisms. The present study was designed to clarify the preventive mechanisms of type I IFNs in the progression of fibrosis for the establishment of a more effective therapy. A murine fibrosis model comprising immunological reactions was induced by the administration of concanavalin A (0·3 mg/body) into mice once a week for 4 weeks. Liver injury and the degree of fibrosis were determined by measuring the serum alanine aminotransferase activities and liver hydroxyproline contents with or without IFN‐β pretreatment. IFN‐β suppressed the hepatocellular injury and increased the hydroxyproline content induced by repeated concanavalin A injections, but had no effect on established fibrosis. Furthermore, IFN‐β reduced the expressions of transforming growth factor‐β, basic fibroblast growth factor, collagen type I A2 and tissue inhibitor of metalloproteinase 1 messenger RNAs, which are related to the progression of liver fibrosis. The IFN‐β reduced the liver injury and fibrosis induced by immunological reactions. These data suggest that type I IFNs suppress the progression of cirrhosis through inhibition of repeated hepatocellular injury and/or factors that promote the liver fibrosis induced by hepatitis virus infection.
Hepatology Research | 2007
Tomoko Date; Michiko Miyamoto; Takanobu Kato; Kenichi Morikawa; Asako Murayama; Daisuke Akazawa; Jun-Ichi Tanabe; Saburo Sone; Masashi Mizokami; Takaji Wakita
Aim: The hepatitis C virus (HCV) strain JFH‐1 was cloned from a patient with fulminant hepatitis. A JFH‐1 subgenomic replicon and full‐length JFH‐1 RNA efficiently replicate in cultured cells. In this study, an infectious, selectable HCV replicon containing full‐length JFH‐1 cDNA was constructed.
Hepatology Research | 2009
Tomohiko Ohashi; Jun-Ichi Tanabe; Tetsuya Ishikawa; Akihiko Okumura; Ken Sato; Minoru Ayada; Naoki Hotta; Teiji Kuzuya; Hiroyasu Ito; Haruhisa Nakao; Masashi Yoneda; Shinichi Kakumu
Aim: Human hepatocytes are known to express an array of inflammatory cytokines and chemokines. In this study, we examined the potential roles of hepatocytes in regulating immune responses in the liver, by assessing the induction of Th1‐ or Th2‐specific chemokines in HepG2 cells after various inflammatory stimulations.
Hepatology Research | 2006
Saburo Sone; Akiko Izawa; Hideki Narumi; Akemi Kajita; Jun-Ichi Tanabe; Fumihiro Taguchi
Aim: To determine the differences in efficacy between therapy using IFN‐β and ribavirin, and using IFN‐α and ribavirin.
Journal of Medical Virology | 2007
Kenichi Morikawa; Zijiang Zhao; Tomoko Date; Michiko Miyamoto; Asako Murayama; Daisuke Akazawa; Jun-Ichi Tanabe; Saburo Sone; Takaji Wakita
Archive | 2005
Takaji Wakita; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Jun-Ichi Tanabe; Saburo Sone
Archive | 2005
Takaji Wakita; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Ralf Bartenschlager; Jun-Ichi Tanabe; Saburo Sone
Hepatology Research | 2006
Minoru Ayada; Tetsuya Ishikawa; Akihiko Okumura; Jun-Ichi Tanabe; Hiroyasu Ito; Tomohiko Ohashi; Eiji Matsumoto; Ken Sato; Naoki Hotta; Yoshitaka Fukuzawa; Sinichi Kakumu
Archive | 2005
Takaji Wakita; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Ralf Bartenschlager; Jun-Ichi Tanabe; Saburo Sone
Archive | 2006
Jun-Ichi Tanabe; Saburo Sone; Takaji Wakita; Koji Ishii; Ryosuke Suzuki; Tetsuro Suzuki; Tatsuo Miyamura